Semaglutide for Alcohol Use Disorder

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
University of North Carolina, Chapel Hill
Study ID
NCT05520775
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide (subcutaneous)
  • Sham/placebo — DRUG
    Sham subcutaneous injection

Study Details

This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).

Key Dates

Start date
Sep 2, 2022
Status verified
May 2024
Primary completion
Apr 12, 2024
Completion
Apr 19, 2024

Study Design

Enrollment
48 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Semaglutide
    Participants will receive semaglutide via subcutaneous injections at escalating doses (.25mg to 1.0mg) over 9 weeks.
  • Sham Comparator: Sham/Placebo
    Participants will receive sham subcutaneous injections over 9 weeks.

Primary Outcome Measure

Change in Alcohol Consumed [ Time Frame: Baseline (Week 0) to post-medication (Week 8) ]

Locations (1)

FacilityCityStateZIPSite coordinators
UNC-Chapel HillChapel HillNorth Carolina27599-

Related coverage on Hipa.ai

Find similar trials in Chapel Hill, NC

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
UNC-Chapel Hill· Chapel Hill, NC

Related Studies